Queen Elizabeth II a life sciences perspective

Queen Elizabeth II was a stateswoman, not a scientist. But throughout her reign, she championed and embraced life science innovation. She made sure our society thought through and got comfortable with, the implications of what became scientifically possible.

Her accession to the throne in 1953 came in the same year as Crick and Watson discovered DNA. She has reigned throughout the modern era of biotechnology. And her longevity enabled her to span the full arc of the life science innovation life cycle. DNA was just a scientific idea and paper at the start of her time on the throne.

63 years later she officially opened the Crick Institute in London in November 2016, the largest life science discovery institute in Europe. On that occasion, I had the pleasure of hearing the Queen speak, although I didn’t get to go on the lab tour where she sequenced the genome of Sir Paul Nurse in minutes.

The Queen, with The Duke of Edinburgh, opens the Francis Crick Institute
© The Queen, with The Duke of Edinburgh, opens the Francis Crick Institute, source: The Royal Household


Our sector should never forget that the Queen took an active and personal interest in promoting UK early-stage life science entrepreneurship. She both hosted and attended the Buckingham Palace Pitch at the Palace events. The 2016 event was specifically focused on the promise of biotechnology.

But perhaps most important for our sector was that the Queen recognized the importance of the public acceptance of change and those that enabled it to happen.

As the formal leader of the Church of England, the Queen put no moral or ethical barriers in the way of the development of human embryology and fertilization in the 1980s. She made ethicist Mary Warnock a Companion of Honour in 2017. We should remember the debate back then about human fertility treatment and experiments using human embryos. I believe the Queen strongly admired the way in which the Warnock committee managed to get to an ethical consensus that people understood as well as shared. Its effect – expressed in the landmark UK Human Fertilisation and Embryology Act of 1990 - was to require licensing for procedures such as in vitro fertilisation and to ban research using human embryos more than 14 days old. A positive side effect of this legislation was the space for life science research and development. Regulated innovation progressed in the UK whilst the USA went through an early “culture war” that blocked scientific development. The legacy today is the UK’s continued leadership in protecting future generations from the risk of mitochondrial disease. As a Brit, whenever I visit California, it is the lack of effective societal facilitators for this type of debate that strikes me the most.

The Queen’s acceptance and adoption of life science innovation was particularly crucial towards the end of her life during the COVID pandemic. I remember the discussion at the Vaccine Taskforce Steering Board about the vital importance of widespread public take-up of the vaccine of well-known figures being publicly pro-vaccine. The Queen “letting it be known” that she and her husband Prince Philip both had the vaccine within weeks of it being licensed in January 2020 was key to ensuring massive takeup, especially amongst the oldest generation in our society. There was no demand from the Palace that she be first, but she certainly led her age cohort, in line with the best public health guidance.

We will now see weeks of ceremony – and the state funeral at Westminster Abbey. As I have often remarked to overseas visitors – it is a sacred place where Britain has honoured both its Royal family and its scientists since Sir Isaac Newton. The Queen enabled our country to become quietly comfortable with the life science revolution she reigned over – our ecosystem is stronger and embedded in our society as a result. She will be missed.         

Steve Bates headshot



Steve Bates OBE
CEO, BioIndustry Association

More news and updates

The UK's genomics sector: Poised for continued growth and impact

Genomics has become an integral part of the UK's healthcare system, revolutionising patient care and driving innovation within both small and medium-sized enterprises (SMEs) and large pharmaceutical companies. Our new report, Genomics nation 2023, highlights the profound impact of genomics on the UK's life sciences sector and public health system.

BIA announces its Charity Partnership for 2024 with RNID

BIA is thrilled to announce its charity partnership of the year for 2024 with RNID, the national charity supporting the 12 million people in the UK who are deaf, have hearing loss or tinnitus. 

CEO Update - 4 December 2023

UK Biobank is a British success story that puts us at the heart of a key global technology of this century. Last week, UK Biobank published the world’s largest collection of full human genomes. Set up 20 years ago, the charity UK Biobank recruited half a million altruistic volunteers to create the world’s most comprehensive source of health data.

bioProcessUK 2023: Honouring excellence, unveiling future leaders 

In a symphony of innovation and camaraderie, the 20th anniversary bioProcessUK conference swept through Brighton, creating an unforgettable experience for the life sciences and biotech community.